Complete financial analysis of Trevi Therapeutics, Inc. (TRVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trevi Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Gulf Energy Development Public Company Limited (GULF.BK) Income Statement Analysis – Financial Results
- HB Stockholdings Limited (HBSTOCK.BO) Income Statement Analysis – Financial Results
- The Valens Company Inc. (VLNS.TO) Income Statement Analysis – Financial Results
- Ackermans & Van Haaren NV (AVHNY) Income Statement Analysis – Financial Results
- Mojave Brands Inc. (HHPHF) Income Statement Analysis – Financial Results
Trevi Therapeutics, Inc. (TRVI)
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 123.00K | 43.00K | 50.00K | 47.00K | 39.00K | 23.00K | 0.00 | 4.00K |
| Gross Profit | -123.00K | -43.00K | -50.00K | -47.00K | -39.00K | -23.00K | 0.00 | -4.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.68M | 19.83M | 22.98M | 22.33M | 19.34M | 14.07M | 6.10M | 6.91M |
| General & Administrative | 9.95M | 10.07M | 9.49M | 10.16M | 7.31M | 4.34M | 2.14M | 1.66M |
| Selling & Marketing | 287.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.00K |
| SG&A | 10.24M | 10.07M | 9.49M | 10.16M | 7.31M | 4.34M | 2.14M | 1.71M |
| Other Expenses | 0.00 | 719.00K | -375.00K | -287.00K | 577.00K | -2.24M | -24.00K | 0.00 |
| Operating Expenses | 33.92M | 29.91M | 32.48M | 32.49M | 26.65M | 18.41M | 8.24M | 8.62M |
| Cost & Expenses | 33.92M | 29.91M | 32.48M | 32.49M | 26.65M | 18.41M | 8.24M | 8.63M |
| Interest Income | 4.75M | 1.74M | 10.00K | 178.00K | 792.00K | 156.00K | 69.00K | 2.61M |
| Interest Expense | 391.00K | 780.00K | 1.20M | 456.00K | 0.00 | 174.00K | 3.34M | 0.00 |
| Depreciation & Amortization | 123.00K | 43.00K | 50.00K | 47.00K | 39.00K | 23.00K | 4.00K | 4.00K |
| EBITDA | -33.80M | -29.86M | -32.43M | -32.44M | -26.61M | -18.39M | -8.19M | -8.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -33.92M | -29.91M | -32.48M | -32.49M | -26.65M | -18.41M | -8.24M | -8.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.83M | 719.00K | -1.49M | -287.00K | 577.00K | -2.26M | -4.65M | -2.47M |
| Income Before Tax | -29.10M | -29.19M | -33.96M | -32.78M | -26.07M | -20.67M | -12.89M | -11.10M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -32.00K | -36.00K | -21.00K | -18.00K | -18.00K | -124.00K | -26.00K | -8.00K |
| Net Income | -29.07M | -29.15M | -33.94M | -32.76M | -26.05M | -20.55M | -12.86M | -11.09M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.29 | -0.45 | -1.49 | -1.81 | -2.22 | -2.29 | -1.43 | -0.69 |
| EPS Diluted | -0.29 | -0.45 | -1.49 | -1.81 | -2.22 | -2.29 | -1.43 | -0.69 |
| Weighted Avg Shares Out | 99.03M | 64.54M | 22.84M | 18.06M | 11.74M | 8.97M | 8.97M | 16.14M |
| Weighted Avg Shares Out (Dil) | 99.03M | 64.54M | 22.84M | 18.06M | 11.74M | 8.97M | 8.97M | 16.14M |
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:00 p .m.
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Corporate presentation will be held on Wednesday, December 4, 2024, at 1:00 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF),...
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of...
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
NEW HAVEN, Conn. , Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough...
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. ,...
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.
NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough...
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn. , Sept. 26, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing...
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASDAQ: TRVI, which don't yet have any products approved by the Food and Drug...
Source: https://incomestatements.info
Category: Stock Reports